- Product Details
Keywords
- Linaclotide,Linaclotídeo,Linaclotida,Линаклотид
- Линаклотид ацетат,Acetato de linaclotida
- Acétate de linaclotide, Acetato de linaclotídeo
Quick Details
- ProName: Linaclotide API Powder to Treat Gastro...
- CasNo: 851199-59-2
- Molecular Formula: C59h79n15o21s6
- Appearance: white to off white
- Application: Linaclotide is a once-daily, orally ad...
- DeliveryTime: Ready in Stock
- PackAge: Aluminum Foil Bag
- Port: HK/Shenzhen
- ProductionCapacity: 500 Kilogram/Year
- Purity: ≥98%
- Storage: 2-8 degree
- Transportation: Cold chain and cool storage delivery f...
- LimitNum: 1 Gram
Superiority
The first listed company in peptides industry, mature process, stable and advaced technology,API capacity reachease to 500kg with 3 main factory sites.
Details
Linaclotide
Product Description
CAS Registry Number: 851199-59-2
Molecular Formula: C59H79N15O21S6
Molecular Weight: 1526.8
Density: 1.6 g/cm3
Boiling point: 2045.0 °C at 760 mmHg
Appearance:white or off-white crystalline powder
Purity: 98% MIN
Linaclotide is a once-daily, orally administered, first-in-class agonist of guanylate cyclase-C that is minimally absorbed. It is being developed to treat gastrointestinal disorders. Linaclotide has received its first global approval in the US for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation (CIC), and a marketing submission has been filed in the EU for IBS-C. This article summarizes the milestones in the development of linaclotide leading to this first approval for IBS-C and CIC.
Contents of testing |
Specifications |
||
Appearance |
White or almost white crystalline powder |
||
Identity by HPLC |
The reaction is same with the reference substance |
||
Amino Acid Composition |
±20% of theoretical |
||
Purity (HPLC) |
≥ 98.0% |
||
Related Substance(By HPLC) |
Total Impurities(%)≤ 2.0% Largest Single Impurity(%)≤ 1.0% |
||
Acetate Content(By HPLC) |
≤15% |
||
Water Content(By HPLC) |
≤5.0% |
||
Bacterial Endotoxins |
≤5IU/mg |